Harrow, Inc. (HROW)
HROWNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$29.40
+0.0300 (+0.10%) today
Closed, Nov 11, 4:00 PM ET
- Market cap
- $1.10bn
- P/E
- –
- EPS, last 4 quarters
- $-0.5900
- Dividend yield
- –
- Day range
- –
- 52-week range
- $25.76 to $54.85
- Average volume
- –
- Previous close
- $29.37
Analysts
8 coveringBuy8 buy, 0 hold, 0 sell
Targets a year out average $63.67, +116.6% from here
Earnings
next estimate $0.8800Next report
Dec 2025
-35.0%
Mar 2026
-46.5%
Jun 2026
-47.8%
Sep 2026
-7.7%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $89.09m | $44.20m | $70.66m | $99.30m |
| Gross profit | $70.62m | $27.05m | $50.36m | $74.90m |
| Operating income | $15.59m | -$22.08m | -$11.01m | $11.47m |
| Net income | $6.63m | -$27.60m | -$17.27m | $9.76m |
Last four quarters: revenue $303.25m, margin -9.4%, free cash flow -$20.35m
News
8 latest- Harrow (HROW) Q3 2026 Earnings Call TranscriptThe Motley Fool · 1 day ago
- Notable Tuesday Option Activity: HROW, CLOV, RCATBNK Invest · 1 day ago
- Harrow Q3 Earnings Call HighlightsMarketBeat · 1 day ago
- Harrow, Inc. Reports Record Third Quarter 2026 Revenue of $99.3 millionFintel · 2 days ago
- Harrow (HROW) Reports Q3 Earnings: What Key Metrics Have to SayZacks · 2 days ago
- Harrow (HROW) Q3 Earnings Lag EstimatesZacks · 2 days ago
- Profound Medical (PROF) Reports Q3 Loss, Beats Revenue EstimatesZacks · 6 days ago
- Prelude Therapeutics Incorporated (PRLD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks · Nov 4, 2026
The company
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma, and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- harrow.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.